Protagonist Therapeutics Announced A Late-breaking Presentation At The American Academy Of Dermatology 2024 Annual Meeting With Results From The Phase 2b FRONTIER 2 Long-term Extension Study Evaluating JNJ-2113 For Moderate-to-severe Plaque Psoriasis
Author: Benzinga Newsdesk | March 11, 2024 07:40am
JNJ-2113 was jointly discovered and is being developed pursuant to the license and collaboration agreement between Protagonist and J&J, which retains exclusive worldwide rights to develop JNJ-2113 in Phase 2 clinical trials and beyond, and to commercialize compounds derived from the research conducted pursuant to the agreement against a broad range of indications. The license and collaboration agreement, established in 2017, enabled the companies to work together to discover and develop next-generation compounds that ultimately led to JNJ-2113.
Posted In: JNJ PTGX